The game between Esai, Ranbaxy, Teva and FDA for Aricept

I have came across a nice compiled study of the Aricept case. Recently Ranbaxy got the approval and entitled 180 days exclusivity and Teva's generic launch was delayed until the expiry of 180 days exclusivity of Ranbaxy.
The whole story is very well explained here

Ranbaxy got final approval for Aricept

Indian pharma major, Ranbaxy got the final approval from USFDA for marketing of Aricept generic version. Additionally Ranbaxy holds the 180 day exclusivity for this product which will allow them to sell the generic version in US market without any other generic competition. Therefore Ranbaxy expecting US $200 million from this 180 days selling of generic version of Aricept. Aricept is the brand name containing Donepezil as active ingredient and is used for Alzheimer's disease.